Temporal trends in generic and brand prices of antiretroviral medicines procured with donor funds in developing countries

Journal of Generic Medicines

Volumn 7, Issue 2, 2010, Pages 159-175

  Waning, Brenda ^a   Kaplan, Warren ^a   Fox, Matthew P ^a   Boyd Boffa, Mariah ^b   King, Alexis C ^c   Lawrence, Danielle A ^a   Soucy, Lyne ^d   Mahajan, Sapna ^a   Leufkens, Hubert G ^e   Gokhale, Manjusha ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Access; Antiretroviral; Policy; Price; Procurement; Transparency

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GENERIC DRUG; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DEVELOPING COUNTRY; DRUG COST; DRUG DOSAGE FORM; DRUG INDUSTRY; FUNDING; HEALTH CARE POLICY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PURCHASING; TABLET; TREND STUDY; WORLD HEALTH ORGANIZATION;

EID: 77951873988     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/jgm.2010.6     Document Type: Article

References (31)

1. Nicholson, W. (2004) Intermediate Microeconomics and Its Application, 9th edn. Mason, OH: Thomson South-Western.
2. Bate, R., Coticelli, P., Tren, R. and Attaran, A. (2008) Antimalarial drug quality in the most severely malarious parts of Africa - A six country study. PLoS ONE (cited 21 May) 3 (5) : 1-3, http://www.plosone.org/article/info: doi%2F10.1371%2 Fjournal.pone.0002132. (Pubitemid 352025174)
3. Cockburn, R., Newton, P. N., Agyarko, E. K., Akunyili, D. and White, N. J. (2008) The global threat of counterfeit drugs: Why industry and governments must communicate the dangers. PLoS Medicine (cited 21 May) 2 (4) : 302-308, http://medicine.plosjournals.org/archive/1549-1676/2/4/pdf/10.1371-journal.pmed. 0020100-S.pdf. (Pubitemid 40721074)
4. Seiter, A. (2005) Pharmaceuticals: Cost containment, pricing, reimbursement. Washington DC: World Bank. HNP Brief no. 7 (cited 5 February), p. 7, http://siteresources.worldbank.org/HEALTH NUTRITIONANDPOPULATION/Resources/ 281627-1109774792596/HNPBrief-7.pdf.
5. Zerda, A., Velásquez, G., Tobar, F. and Vargas, J. E. (2002) Health Insurance Systems and Access to Medicines - Case Studies from: Argentina, Chile, Colombia, Costa Rica, Guatemala and the United States of America. Washington DC: Pan American Health Organization (cited 15 April 2008), p. 96, http://www.who.int/medicinedocs/en/d/Jh3012e/#Jh3012e.
6. The Global Fund to fi ght AIDS, Tuberculosis and Malaria. (2002) Report of the 3rd Board Meeting. Geneva (CH) : The Global Fund, October 2002 (cited 29 April 2008), p. 53, http://www.theglobal fund.org/en/fi les/publicdoc/ Third%20Board%20 Meeting.pdf.
7. The Global Fund to Fight AIDS, Tuberculosis and Malaria. (2003) Report of the Portfolio Management and Procurement Committee (PMPC). Report of the 4th Board Meeting. Geneva (CH) : The Global Fund, January 2003 (cited 29 April 2008), p. 49, http://www.theglobalfund.org/en/fi les/boardmeeting4/ GF%20B4%2007%20Procurement%20and%20 Management.pdf.
8. The Global Fund to Fight AIDS, Tuberculosis and Malaria. (2007) Report of the Portfolio Management and Procurement Committee (PMPC). Report of the 15th Board Meeting. Geneva (CH) : The Global Fund April 2007 (cited 5 May 2008), p. 40, http://www.theglobalfund.org/en/fi les/boardmeeting15/GF-BM15-06-ReportPSC. pdf.
9. The Global Fund to Fight AIDS, Tuberculosis and Malaria. (2008) The Price Reporting Mechanism. The Global Fund to fight AIDS, Tuberculosis and Malaria. Geneva (CH) (cited 4 February 2008), http://www.theglobalfund.org/en/funds- raised/price-reporting/default.asp.
10. World Health Organization. (2008) Global Price Reporting Mechanism. Geneva (CH) : World Health Organization (cited 4 February 2008), http://www.who.int/hiv/amds/gprm/en/.
11. World Health Organization. (2007) A Summary Report from the Global Price Reporting Mechanism on Antiretroviral Drugs. Geneva (CH), October 2007 (cited 8 May 2008), p. 11, http://www.who.int/hiv/amds/GPRMsummary ReportOct07.pdf.
12. Gelders, S., Ewen, M., Noguchi, N. and Laing, R. (2005) Price, Availability and Affordability: An International Comparison of Chronic Disease Medicines. Geneva (CH) : World Health Organization/Health Action International, WHO-EM/EDB/068/E/05.06/3000. December 2005 (cited 2 November 2007), p. 169, http://www.haiweb.org/medicineprices/30052006/CHRONICANN.pdf.
13. Babar, Z., Ibrahim, M., Singh, H., Bukahri, N. and Creese, A. (2007) Evaluating drug prices, availability, affordability, and price components: Implications for access to drugs in Malaysia. PLoS Medicine (cited 22 May 2008) 4 (3) : 466-475, http://medicine.plosjournals.org/perlserv/?request=get-document & doi=10.1371/journal.pmed.0040082. (Pubitemid 46495314)
14. Health Action International. (2008) Medicine prices, availability, affordability and price components. Health Action International (cited 6 May 2008), http://www.haiweb.org/medicineprices/.
15. Médicins sans Frontières. (2001-2008) Untangling the Web of Price Reductions: A Pricing Guide for the Purchase of ARVs for Developing Countries, 1-11th edn. Geneva, Switzerland: Médicins sans Frontières.
16. Management Sciences for Health. (2006) International Drug Price Indicator Guide. Cambridge, MA: Management Sciences for Health (cited 17 January 2008), http://erc.msh.org/mainpage.cfm?fi le =1.0.htm & module=Dmp & language=English.
17. World Health Organization. (2008) A Summary Report from the Global Price Reporting Mechanism on Antiretroviral Drugs. Geneva (CH), February 2008 (cited 8 May 2008), p. 11, http://www.who.int/hiv/amds/GPRMFeb2008.pdf.
18. World Health Organization. (2008) Transaction prices for antiretroviral medicines and diagnostics from 2004 to 2007. WHO, Geneva (CH), 2008 July.
19. Vasan, A., Hoos, D., Mukherjee, J. S., Farmer, P. E., Rosenfield, A. G. and Perriens, J. H. (2006) The pricing and procurement of antiretroviral drugs: An observational study of data from the global fund. Bulletin of the World Health Organization 84 (5) : 393-398.
20. Chien, C. V. (2007) HIV/AIDS drugs for sub-Saharan Africa: How do brand and generic supply compare? PLoS ONE (cited 21 May 2008) 2 (3) : 1-6, http://www.plosone.org/article/info: doi%2F10.1371%2Fjournal.pone.0000278.
21. Nunn, A. S., Fonseca, E. M., Bastos, F. I., Gruskin, S. and Salomon, J. A. (2007) Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Medicine (cited 22 April 2008) 4 (11) : 1804-1817, http://medicine.plosjournals.org/archive/1549-1676/4/11/ pdf/10.1371-journal.pmed.0040305-S.pdf. (Pubitemid 350220533)
22. Barnighausen, T. and Bloom, D. E. (2007) Conditional Scholarships for HIV/AIDS Health Workers: Educating and Retaining the Workforce to Provide Antiretroviral Treatment in Sub-Saharan Africa. Cambridge, MA: Harvard Initiative for Global Health. Program on the Global Demography of Aging. Working Paper no. 24 (cited 4 November 2007), p. 61, http://www.hsph.harvard.edu/pgda/ Working%20 Papers/2007/pgda-wp24-2007.pdf.
23. International Monetary Fund. (2007) World Economic Outlook Database. Washington DC: International Monetary Fund (cited 30 November 2007), http://www.imf.org/external/pubs/ft/weo/2007/01/data/index.aspx.
24. World Health Organization. (2004) Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach 2003 Revision. Geneva (CH) : World Health Organization (cited 17 January 2008), p. 68, http://www.who.int/hiv/pub/prev-care/en/arvrevision2003en. pdf.
25. World Health Organization. (2006) Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-limited Settings: Towards Universal Access. Geneva (CH) : World Health Organization (cited 17 January 2008), p. 144, http://www.who.int/hiv/pub/guidelines/WHO%20Adult%20ART%20 Guidelines.pdf.
26. World Health Organization. (2007) Preferred Antiretroviral Medicines for Treating and Preventing HIV Infection in Younger Children. Report of the WHO Paediatric Antiretroviral Working Group, WHO. Geneva (CH) (cited 14 September 2008) http://www.who.int/hiv/events/paediatricmeetingreport.pdf.
27. International Center for AIDS Care and Management Programs. (2006) Pediatric Antiretroviral Dosing in Resource-Limited Settings. New York City, USA (cited 2 October 2008), p. 2, http://www.cdc.gov/nchstp/od/GAP/docs/program- areas/pmtct/Peds%20Dosing%20 Guide.pdf.
28. United States Government Accountability Office. (2005) Global HIV/AIDS epidemic: Selection of antiretroviral medications provided under US emergency plan is limited. GAO - 05-133. Washington DC, USA, January 2005 (cited 17 January 2008), p. 43, http://www.gao.gov/new.items/d05133.pdf.
29. World Bank. Country classification. World Bank, Washington DC, USA (cited 10 November 2007), http://web.worldbank.org/.
30. World Health Organization. WHO Regional Offices. Geneva (CH) : World Health Organization (cited 14 September 2008), http://www.who.int/about/regions/ en/index.html.
31. Medicines Transparency Alliance. (2008) Department for International Development. Health Resource Center, London, UK (cited 10 May 2008), http://www.dfi dhealthrc.org/MeTA/index.html.